Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer

(E-pub Ahead of Print)

Author(s): Jiayi Gong, Huaxi Xu*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: The antimetabolite, 5-fluorouracil (5-FU), is the only chemotherapeutic drug to significantly improve 12-month survival rates of patients with colorectal cancer (CRC). However, resistance to 5-FU is a major obstacle to effective treatment. The mechanism of 5-FU resistance has been discovered but is not fully known. Nuclear factor-erythroid 2-related factor 2 (Nrf2), a master regulator of cellular defense against oxidative and electrophilic stresses, is considered a major factor in 5-FU resistance.

Objective: The current study was conducted to discuss the role and mechanisms of Nrf2 in 5-FU resistance and to search for medicines or compounds that can reverse Nrf2-mediated 5-FU resistance.

Methods: Literature was obtained by defining specific search terms and searching several databases.

Results: Previous study suggested that overactivation of Nrf2 contributed to 5-FU resistance by regulating many cytoprotective genes. Interestingly, several medicines and compounds can repress 5-FU resistance mediated of Nrf2.

Conclusion: This review describes the major 5-FU-resistance mechanisms of Nrf2 and summarized the medicines/compounds that can overcome them.

Keywords: Colorectal cancer (CRC), 5- fluorouracil (5-FU), resistance, Nrf2, repress, medicine, compound.

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 28 January, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1871520621666210129094354
Price: $95

Article Metrics

PDF: 231